Cardiol Hits Phase III MAVERIC Enrollment Target Early, Expands Trial to 150 Patients
CRDL has more than doubled off its 52-week low of $0.88.
Summary
Cardiol Therapeutics hit its Phase III MAVERIC enrollment target early and will expand the trial to up to 150 patients after a blinded review showed fewer recurrences than expected. Topline results shift to mid-2027, with cash runway into Q1 2028.
Key Events · Product Development and Regulatory · CRDL
-
Phase III Enrollment Target Achieved Early
110 patients enrolled in MAVERIC as of September 23, 2026, ahead of the company's end-of-September guidance.
-
Trial Expansion to 150 Patients
MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to preserve statistical power after a blinded review showed fewer-than-expected recurrences.
-
Topline Results Delayed to Mid-2027
Topline data now anticipated in mid-2027, compared with previous Q1 2027 guidance, reflecting the expanded enrollment.
-
Cash Runway Extended into Q1 2028
Existing capital expected to fund MAVERIC completion, with cash runway extending into Q1 2028.
Analysis · CRDL · Life Sciences
Cardiol Therapeutics achieved its 110-patient enrollment target for the pivotal Phase III MAVERIC trial ahead of schedule and, on the recommendation of its Steering Committee, will expand enrollment to up to 150 patients. The expansion follows a blinded review showing fewer-than-expected pericarditis recurrences — an observation management views as encouraging. The trade-off is a timeline shift: topline results move from Q1 2027 to mid-2027. The company states existing capital is sufficient to complete the trial, with cash runway now extending into Q1 2028.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDL was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.8M. The 52-week trading range was $0.88 to $2.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.